CN107404922B - 乳基蛋白质水解物及由其制备的组合物 - Google Patents
乳基蛋白质水解物及由其制备的组合物 Download PDFInfo
- Publication number
- CN107404922B CN107404922B CN201680017233.XA CN201680017233A CN107404922B CN 107404922 B CN107404922 B CN 107404922B CN 201680017233 A CN201680017233 A CN 201680017233A CN 107404922 B CN107404922 B CN 107404922B
- Authority
- CN
- China
- Prior art keywords
- milk
- bacillus
- aspergillus
- protease
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 235000013336 milk Nutrition 0.000 title claims abstract description 32
- 210000004080 milk Anatomy 0.000 title claims abstract description 32
- 239000008267 milk Substances 0.000 title claims abstract description 32
- 239000003531 protein hydrolysate Substances 0.000 title claims abstract description 30
- 239000000203 mixture Substances 0.000 title claims description 39
- 108010009736 Protein Hydrolysates Proteins 0.000 title claims description 22
- 239000004365 Protease Substances 0.000 claims abstract description 57
- 238000000034 method Methods 0.000 claims abstract description 47
- 241000228212 Aspergillus Species 0.000 claims abstract description 39
- 108091005804 Peptidases Proteins 0.000 claims abstract description 37
- 241000193830 Bacillus <bacterium> Species 0.000 claims abstract description 35
- 239000000463 material Substances 0.000 claims abstract description 30
- 235000019419 proteases Nutrition 0.000 claims abstract description 26
- 101710184263 Alkaline serine protease Proteins 0.000 claims abstract description 23
- 108010004032 Bromelains Proteins 0.000 claims abstract description 20
- 235000019835 bromelain Nutrition 0.000 claims abstract description 20
- 102000014171 Milk Proteins Human genes 0.000 claims abstract description 19
- 108010011756 Milk Proteins Proteins 0.000 claims abstract description 19
- 230000008569 process Effects 0.000 claims abstract description 19
- 230000000813 microbial effect Effects 0.000 claims abstract description 18
- 235000021239 milk protein Nutrition 0.000 claims abstract description 16
- 238000002360 preparation method Methods 0.000 claims abstract description 15
- 230000003301 hydrolyzing effect Effects 0.000 claims abstract description 14
- 238000006460 hydrolysis reaction Methods 0.000 claims description 42
- 102000035195 Peptidases Human genes 0.000 claims description 36
- 230000007062 hydrolysis Effects 0.000 claims description 36
- 239000000413 hydrolysate Substances 0.000 claims description 35
- 108010046377 Whey Proteins Proteins 0.000 claims description 27
- 102000004190 Enzymes Human genes 0.000 claims description 25
- 108090000790 Enzymes Proteins 0.000 claims description 25
- 102000007544 Whey Proteins Human genes 0.000 claims description 25
- 229940088598 enzyme Drugs 0.000 claims description 25
- 235000013350 formula milk Nutrition 0.000 claims description 20
- 240000006439 Aspergillus oryzae Species 0.000 claims description 13
- 235000002247 Aspergillus oryzae Nutrition 0.000 claims description 13
- 108090000145 Bacillolysin Proteins 0.000 claims description 13
- 208000009793 Milk Hypersensitivity Diseases 0.000 claims description 13
- 102000002704 Leucyl aminopeptidase Human genes 0.000 claims description 12
- 108010004098 Leucyl aminopeptidase Proteins 0.000 claims description 12
- 108090000284 Pepsin A Proteins 0.000 claims description 11
- 102000057297 Pepsin A Human genes 0.000 claims description 11
- 235000021119 whey protein Nutrition 0.000 claims description 11
- 108010076119 Caseins Proteins 0.000 claims description 9
- 239000005018 casein Substances 0.000 claims description 9
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims description 9
- 235000021240 caseins Nutrition 0.000 claims description 9
- 235000016709 nutrition Nutrition 0.000 claims description 9
- 241000194108 Bacillus licheniformis Species 0.000 claims description 8
- 230000000774 hypoallergenic effect Effects 0.000 claims description 8
- 108010056079 Subtilisins Proteins 0.000 claims description 7
- 102000005158 Subtilisins Human genes 0.000 claims description 7
- 239000000047 product Substances 0.000 claims description 7
- 244000063299 Bacillus subtilis Species 0.000 claims description 6
- 235000014469 Bacillus subtilis Nutrition 0.000 claims description 6
- 108090000787 Subtilisin Proteins 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 235000015872 dietary supplement Nutrition 0.000 claims description 4
- 238000000108 ultra-filtration Methods 0.000 claims description 4
- 235000008452 baby food Nutrition 0.000 claims description 3
- 235000020218 follow-on milk formula Nutrition 0.000 claims description 3
- 230000002779 inactivation Effects 0.000 claims description 3
- 238000001471 micro-filtration Methods 0.000 claims description 3
- 108060003393 Granulin Proteins 0.000 claims 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 27
- 235000018102 proteins Nutrition 0.000 description 27
- 102000004169 proteins and genes Human genes 0.000 description 27
- 108090000623 proteins and genes Proteins 0.000 description 27
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 24
- 239000005862 Whey Substances 0.000 description 16
- 102000004196 processed proteins & peptides Human genes 0.000 description 16
- 229910052757 nitrogen Inorganic materials 0.000 description 12
- 206010020751 Hypersensitivity Diseases 0.000 description 10
- 230000007815 allergy Effects 0.000 description 10
- 102000008192 Lactoglobulins Human genes 0.000 description 9
- 108010060630 Lactoglobulins Proteins 0.000 description 9
- 235000001014 amino acid Nutrition 0.000 description 9
- 150000001413 amino acids Chemical class 0.000 description 9
- 239000006041 probiotic Substances 0.000 description 9
- 235000018291 probiotics Nutrition 0.000 description 9
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 8
- 201000010859 Milk allergy Diseases 0.000 description 8
- 208000026935 allergic disease Diseases 0.000 description 8
- 239000008101 lactose Substances 0.000 description 8
- 230000000529 probiotic effect Effects 0.000 description 8
- 241000186605 Lactobacillus paracasei Species 0.000 description 7
- 238000009826 distribution Methods 0.000 description 7
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 6
- 108090000631 Trypsin Proteins 0.000 description 6
- 102000004142 Trypsin Human genes 0.000 description 6
- 239000012588 trypsin Substances 0.000 description 6
- 206010061958 Food Intolerance Diseases 0.000 description 5
- 241000186660 Lactobacillus Species 0.000 description 5
- 235000009508 confectionery Nutrition 0.000 description 5
- 229940039696 lactobacillus Drugs 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 241000194032 Enterococcus faecalis Species 0.000 description 4
- 244000199866 Lactobacillus casei Species 0.000 description 4
- 235000013958 Lactobacillus casei Nutrition 0.000 description 4
- 108010019160 Pancreatin Proteins 0.000 description 4
- 241000191998 Pediococcus acidilactici Species 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 235000020247 cow milk Nutrition 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 239000012467 final product Substances 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 235000020256 human milk Nutrition 0.000 description 4
- 229940055695 pancreatin Drugs 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 241001608472 Bifidobacterium longum Species 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- 108090000317 Chymotrypsin Proteins 0.000 description 3
- 241000193403 Clostridium Species 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 206010025476 Malabsorption Diseases 0.000 description 3
- 208000004155 Malabsorption Syndromes Diseases 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 239000013566 allergen Substances 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 229940009291 bifidobacterium longum Drugs 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 208000019902 chronic diarrheal disease Diseases 0.000 description 3
- 229960002376 chymotrypsin Drugs 0.000 description 3
- 230000001112 coagulating effect Effects 0.000 description 3
- 238000004255 ion exchange chromatography Methods 0.000 description 3
- 229940017800 lactobacillus casei Drugs 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 239000013589 supplement Substances 0.000 description 3
- NHJVRSWLHSJWIN-UHFFFAOYSA-N 2,4,6-trinitrobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O NHJVRSWLHSJWIN-UHFFFAOYSA-N 0.000 description 2
- 241000193798 Aerococcus Species 0.000 description 2
- 244000099147 Ananas comosus Species 0.000 description 2
- 235000007119 Ananas comosus Nutrition 0.000 description 2
- 241000193749 Bacillus coagulans Species 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 241000606125 Bacteroides Species 0.000 description 2
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 description 2
- 241000186016 Bifidobacterium bifidum Species 0.000 description 2
- 241000186015 Bifidobacterium longum subsp. infantis Species 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 238000007399 DNA isolation Methods 0.000 description 2
- 241000194033 Enterococcus Species 0.000 description 2
- 241000194031 Enterococcus faecium Species 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- 241000191953 Kocuria varians Species 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- 102000004407 Lactalbumin Human genes 0.000 description 2
- 108090000942 Lactalbumin Proteins 0.000 description 2
- 240000001046 Lactobacillus acidophilus Species 0.000 description 2
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 2
- 241000194036 Lactococcus Species 0.000 description 2
- 241000192132 Leuconostoc Species 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000192041 Micrococcus Species 0.000 description 2
- 241000235395 Mucor Species 0.000 description 2
- 241000192001 Pediococcus Species 0.000 description 2
- 241000191996 Pediococcus pentosaceus Species 0.000 description 2
- 241000228143 Penicillium Species 0.000 description 2
- 241000191992 Peptostreptococcus Species 0.000 description 2
- 241000235648 Pichia Species 0.000 description 2
- 241000186429 Propionibacterium Species 0.000 description 2
- 241000235527 Rhizopus Species 0.000 description 2
- 241000235070 Saccharomyces Species 0.000 description 2
- 241000191940 Staphylococcus Species 0.000 description 2
- 241000191965 Staphylococcus carnosus Species 0.000 description 2
- 241000191973 Staphylococcus xylosus Species 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- 244000057717 Streptococcus lactis Species 0.000 description 2
- 235000014897 Streptococcus lactis Nutrition 0.000 description 2
- 241000194020 Streptococcus thermophilus Species 0.000 description 2
- 239000012505 Superdex™ Substances 0.000 description 2
- 241000500332 Tetragenococcus halophilus Species 0.000 description 2
- 241000202221 Weissella Species 0.000 description 2
- 238000003916 acid precipitation Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 229940054340 bacillus coagulans Drugs 0.000 description 2
- 229940002008 bifidobacterium bifidum Drugs 0.000 description 2
- 229940004120 bifidobacterium infantis Drugs 0.000 description 2
- 229940009289 bifidobacterium lactis Drugs 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940032049 enterococcus faecalis Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 210000004251 human milk Anatomy 0.000 description 2
- 238000007901 in situ hybridization Methods 0.000 description 2
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- LWGJTAZLEJHCPA-UHFFFAOYSA-N n-(2-chloroethyl)-n-nitrosomorpholine-4-carboxamide Chemical compound ClCCN(N=O)C(=O)N1CCOCC1 LWGJTAZLEJHCPA-UHFFFAOYSA-N 0.000 description 2
- 238000002515 oligonucleotide synthesis Methods 0.000 description 2
- 230000000737 periodic effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 235000019833 protease Nutrition 0.000 description 2
- 229940108461 rennet Drugs 0.000 description 2
- 108010058314 rennet Proteins 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 238000001542 size-exclusion chromatography Methods 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 108090000346 stem bromelain Proteins 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 235000021241 α-lactalbumin Nutrition 0.000 description 2
- 108010051457 Acid Phosphatase Proteins 0.000 description 1
- 102000013563 Acid Phosphatase Human genes 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 241000256844 Apis mellifera Species 0.000 description 1
- 208000002109 Argyria Diseases 0.000 description 1
- 101001051297 Aspergillus oryzae (strain ATCC 42149 / RIB 40) Leucine aminopeptidase A Proteins 0.000 description 1
- 108091005658 Basic proteases Proteins 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 241000234670 Bromeliaceae Species 0.000 description 1
- 102000005575 Cellulases Human genes 0.000 description 1
- 108010084185 Cellulases Proteins 0.000 description 1
- 108010005843 Cysteine Proteases Proteins 0.000 description 1
- 102000005927 Cysteine Proteases Human genes 0.000 description 1
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 241000235035 Debaryomyces Species 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000004262 Food Hypersensitivity Diseases 0.000 description 1
- 241000605909 Fusobacterium Species 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- UCUNFLYVYCGDHP-BYPYZUCNSA-N L-methionine sulfone Chemical compound CS(=O)(=O)CC[C@H](N)C(O)=O UCUNFLYVYCGDHP-BYPYZUCNSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 241000186715 Lactobacillus alimentarius Species 0.000 description 1
- 241001134659 Lactobacillus curvatus Species 0.000 description 1
- 241000218588 Lactobacillus rhamnosus Species 0.000 description 1
- 241000917009 Lactobacillus rhamnosus GG Species 0.000 description 1
- 102100023981 Lamina-associated polypeptide 2, isoform alpha Human genes 0.000 description 1
- 101710097665 Leucine aminopeptidase 1 Proteins 0.000 description 1
- 101710097668 Leucine aminopeptidase 2 Proteins 0.000 description 1
- 102100033292 Leucine-rich repeat-containing protein 7 Human genes 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 241001468189 Melissococcus Species 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 1
- 108091005507 Neutral proteases Proteins 0.000 description 1
- 102000035092 Neutral proteases Human genes 0.000 description 1
- 241000202223 Oenococcus Species 0.000 description 1
- 108010067035 Pancrelipase Proteins 0.000 description 1
- 101710180074 Pepsin F Proteins 0.000 description 1
- 108700020962 Peroxidase Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 101710082688 Probable leucine aminopeptidase 1 Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 101710097834 Thiol protease Proteins 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 238000006959 Williamson synthesis reaction Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 229940025131 amylases Drugs 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 108010067454 caseinomacropeptide Proteins 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000020205 cow's milk formula Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000000909 electrodialysis Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 235000020932 food allergy Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hcl hcl Chemical compound Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 238000003505 heat denaturation Methods 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 235000020215 hypoallergenic milk formula Nutrition 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 108010020132 microbial serine proteinases Proteins 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 229940066716 pepsin a Drugs 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 238000001121 post-column derivatisation Methods 0.000 description 1
- 101710082686 probable leucine aminopeptidase 2 Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000006920 protein precipitation Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000001223 reverse osmosis Methods 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 238000003998 size exclusion chromatography high performance liquid chromatography Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 235000020209 toddler milk formula Nutrition 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C21/00—Whey; Whey preparations
- A23C21/02—Whey; Whey preparations containing, or treated with, microorganisms or enzymes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
- A23J3/00—Working-up of proteins for foodstuffs
- A23J3/30—Working-up of proteins for foodstuffs by hydrolysis
- A23J3/32—Working-up of proteins for foodstuffs by hydrolysis using chemical agents
- A23J3/34—Working-up of proteins for foodstuffs by hydrolysis using chemical agents using enzymes
- A23J3/341—Working-up of proteins for foodstuffs by hydrolysis using chemical agents using enzymes of animal proteins
- A23J3/343—Working-up of proteins for foodstuffs by hydrolysis using chemical agents using enzymes of animal proteins of dairy proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
- A23J3/00—Working-up of proteins for foodstuffs
- A23J3/30—Working-up of proteins for foodstuffs by hydrolysis
- A23J3/32—Working-up of proteins for foodstuffs by hydrolysis using chemical agents
- A23J3/34—Working-up of proteins for foodstuffs by hydrolysis using chemical agents using enzymes
- A23J3/341—Working-up of proteins for foodstuffs by hydrolysis using chemical agents using enzymes of animal proteins
- A23J3/343—Working-up of proteins for foodstuffs by hydrolysis using chemical agents using enzymes of animal proteins of dairy proteins
- A23J3/344—Working-up of proteins for foodstuffs by hydrolysis using chemical agents using enzymes of animal proteins of dairy proteins of casein
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/06—Enzymes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/19—Dairy proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
- C12N9/54—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea bacteria being Bacillus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/58—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from fungi
- C12N9/62—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from fungi from Aspergillus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/63—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from plants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/26—Food, ingredients or supplements targeted to meet non-medical requirements, e.g. environmental, religious
- A23V2200/266—All religious conform ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/54—Proteins
- A23V2250/542—Animal Protein
- A23V2250/5424—Dairy protein
Abstract
本发明公开了用于制备乳蛋白质水解物的方法,该方法包括用微生物碱性丝氨酸蛋白酶联合菠萝蛋白酶、来自曲霉(Aspergillus)的蛋白酶和来自芽孢杆菌(Bacillus)的蛋白酶水解乳基蛋白质材料。
Description
技术领域
本发明涉及包含乳基蛋白质水解物的组合物,所述乳基蛋白质水解物使用来自微生物来源和植物来源的酶。该组合物可掺入到婴儿配方食品和食品补充剂中。
本发明避免使用来源于猪的酶,从而提供具有清真性的组合物。
背景技术
人类母乳和母乳喂养代表婴儿营养方面无可争议的黄金标准。用作人类母乳的替代物或补充物的婴儿配方食品应满足婴儿的营养要求,具有可接受的味道,并且当以处于变态反应和/或食物耐受不良风险的婴儿为目标时,还应为低变应原性的。
已知对牛乳及含有牛乳蛋白质的婴儿配方食品的变态反应是由于这样的事实:牛乳的蛋白质不同于母乳的蛋白质,并且可构成人类的变应原。主要公认的牛乳变应原是α-乳白蛋白(aLA)、β-乳球蛋白(bLG)和牛血清白蛋白(BSA)。
牛乳清蛋白和/或酪蛋白通常用作婴儿配方食品中的乳蛋白质源。
为了减弱变应原性,牛乳蛋白质经酶水解,因此被还原为肽。必须小心监测用于产生这些水解物的水解方法,使得最终产物保留其营养价值和所需的物理特性,但是为低变应原性的。
水解物可被表征为“部分水解物”或“深度水解物”,具体取决于水解反应进行的程度。根据针对牛乳蛋白质变态反应(CMA)的WAO(世界变态反应组织(World AllergyOrganization))指南,目前对深度水解产物(EHP)没有一致的法律/临床定义,但是存在共识:已证明,对于患有牛乳变态反应(CMA)的婴儿,水解制剂是有用的且广泛使用的蛋白质来源。深度水解物可被定义为其中至少95%的蛋白质/肽群具有小于1000道尔顿的分子量,而部分水解物可被定义为其中60%的蛋白质/肽群具有小于1000道尔顿的分子量。这些定义目前在本行业中使用。
欧洲儿科变态反应与临床免疫学会(European Society for PaediatricAllergy and Clinical Immunology,ESPACI)和欧洲儿科胃肠病学、肝脏病学和营养学会(European Society for Paediatric Gastroenterology,Hepatology,and Nutrition,ESPGHAN)均强调,由于深度水解配方食品已被证实具有安全性和低变应原性,应当将其用于IgE介导的CMA(Businco et al.Pediatr Allergy Immunol 1993,4:101-111(Businco等人,《儿科变态反应和免疫学杂志》,1993年,第4卷,第101-111页); et al.Arch DisChild 1999,81:80-84(等人,《儿童疾病档案》,1999年,第81卷,第80-84页);American Academy of Pediatrics,Pediatrics 1989,83:1068-1069(美国儿科学会,《儿科学》,1989年,第83卷,第1068-1069页))。
为优化水解方法,许多组进行了研究。水解反应条件,包括温度和反应器体积、水解循环数、所选的蛋白质底物、酶的类型和浓度,是影响水解反应并因此影响最终产物的物理、化学以及最终生物学特性的许多因素中的一些。
猪类酶,尤其是猪胰酶常用于水解方法。例如,在EP0353122中,使用特定比例的胰蛋白酶和胰凝乳蛋白酶的混合物制备低变应原性的乳清蛋白水解物。WO9304593A1和US5039532A也公开了使用胰蛋白酶和胰凝乳蛋白酶的水解方法,该水解方法包括两步水解反应,在其间具有热变性步骤以确保最终水解物基本上不含完整的变应原蛋白质。这些方法中使用的胰蛋白酶和胰凝乳蛋白酶是由猪胰腺提取物产生的制剂。
市场上存在许多用动物酶制备的含蛋白质水解物的产品。例如,雀巢HA(R)(Nestle HA(R))婴儿配方食品可用使用从动物胰腺提取的胰蛋白酶和胰凝乳蛋白酶产生的水解物来制备。此外,深度水解产物和 也可使用猪胰酶来制备。
本领域需要含有使用非猪类酶制备的蛋白质水解物的产品。有利地,此类产品可具有清真性。但是,基于非猪类酶的水解物应具有与从猪类酶获得的水解物基本上对应的肽谱,并且应当保持低变应原特性。虽然这是一个相当大的挑战,但是特别重要,因为市场上任何新的婴儿配方食品都要遵守严格的监管指南,例如欧盟指令2006/141/EC适用。
本发明解决了对含有使用非猪类酶制备的蛋白质水解物的产品的需求。
发明内容
本发明人监测了包括水解反应性能和肽分子量分布在内的参数,并且确定了向水解物提供所需物理、化学和生物学特性的酶混合物。
本文公开的乳蛋白质水解物可高效地和可再现地生产,具有所需的营养价值,且是低变应原性的。
根据本发明的第一方面,提供了用于制备乳蛋白质水解物的方法,该方法包括用微生物碱性丝氨酸蛋白酶、菠萝蛋白酶、来自曲霉(Aspergillus)的蛋白酶和来自芽孢杆菌(Bacillus)的蛋白酶水解乳基蛋白质材料。
优选地,该方法包括用微生物碱性丝氨酸蛋白酶、菠萝蛋白酶、来自曲霉的两种蛋白酶和来自芽孢杆菌的蛋白酶水解乳基蛋白质材料。
优选地,该微生物碱性丝氨酸蛋白酶为枯草杆菌蛋白酶,优选地为枯草杆菌蛋白酶Carlsberg。
在一个实施方案中,碱性丝氨酸蛋白酶源自芽孢杆菌,优选地源自地衣芽孢杆菌(Bacillus licheniformis)。用于本发明的碱性丝氨酸蛋白酶的一个示例是AlcalaseTM。
优选地,来自曲霉的两种蛋白酶是亮氨酸氨肽酶和曲霉胃蛋白酶1(aspergillopepsin 1)。
优选地,来自曲霉的蛋白酶来自米曲霉(Aspergillus oryzae)。
优选地,来自芽孢杆菌的蛋白酶来自枯草芽孢杆菌(Bacillus subtilis)。
优选地,来自芽孢杆菌的蛋白酶是枯草芽孢杆菌中性蛋白酶。
优选地,该方法包括:
(i)第一水解步骤,包括用微生物碱性丝氨酸蛋白酶水解乳基蛋白质材料;以及
(ii)第二水解步骤,包括用菠萝蛋白酶联合曲霉蛋白酶和芽孢杆菌蛋白酶水解乳蛋白。
该乳基蛋白质材料可以是例如乳清蛋白、酪蛋白或两者的混合物。优选地,该乳基蛋白质材料为乳清蛋白。
优选地,该水解物进一步经受酶失活、微滤和超滤。
在一个特别优选的实施方案中,该蛋白质水解物为深度水解产物,其中水解程度(非蛋白氮/总氮比例,NPN/TN%)大于95%,优选地大于99%。
本发明在提供存在于配方食品(诸如旨在用于喂食对牛乳表现出变态反应的婴儿及儿童的那些)中的“深度”蛋白质水解物方面特别有用。此类水解物优选地针对已被牛乳蛋白致敏的患病(过敏)婴儿及儿童。
因此,根据本发明的另一方面,提供了包含通过本发明的方法获得的乳基蛋白质水解物的组合物。该组合物可以是例如婴儿配方食品、较大婴儿配方食品、婴孩食物配方食品、儿童食品补充剂或成人营养组合物。
在一个优选的实施方案中,所述组合物是婴儿配方食品,优选地是低变应原性的婴儿配方食品。
本发明还提供可用于婴儿、儿童或成人产品的蛋白质水解物、组合物及其制备方法,这些蛋白质水解物、组合物及其制备方法的目标在于提供除与变态反应有关的益处以外的其他益处,诸如促进消化;增强氨基酸、肽和蛋白质的吸收和代谢;促进疾病康复;以及优化氮源的利用。
根据本发明的另一方面,提供了菠萝蛋白酶在制备包含乳基蛋白质材料水解物的组合物中的用途。
优选地,菠萝蛋白酶的使用与微生物碱性丝氨酸蛋白酶和来自本文提及的曲霉属和芽孢杆属菌物种的蛋白酶的使用相结合。
根据本发明的另一方面,提供了根据本发明的方法获得的乳蛋白质水解物在制备婴儿配方食品中的用途。
根据本发明的另一方面,提供了本文所定义的用于减少或预防食物耐受不良、牛乳蛋白质变态反应(CMA)、慢性腹泻和吸收不良的组合物。
根据本发明的另一方面,提供了如本文所定义的该组合物用于减少或预防食物耐受不良、牛乳蛋白质变态反应(CMA)、慢性腹泻和吸收不良的用途。
根据本发明的另一方面,提供了向个体施用本发明的组合物的方法,其中该个体具有食物耐受不良、牛乳蛋白质变态反应(CMA)、慢性腹泻和吸收不良。
附图说明
图1:示出了在两个不同试验(左条为第1试验,右条为第2试验)中测定的使用根据本发明的酶组合的UF渗透物的氨基酸谱。
具体实施方式
本发明的乳基蛋白质水解物通过用本文提及的蛋白酶处理乳基蛋白质材料溶液来获得。
乳基蛋白质材料
乳基蛋白质水解物优选地为乳基蛋白质材料。其可以是基于乳清的蛋白质材料、酪蛋白或基于乳清的蛋白质材料和酪蛋白的混合物。
酪蛋白源可以是酸性酪蛋白或非脂乳固形物。
优选地,乳基蛋白质材料是基于乳清的。
基于乳清的蛋白质材料可以是来自奶酪制作的乳清,尤其是诸如经凝乳酶凝结酪蛋白产生的甜乳清、经酸或酸化发酵剂凝结酪蛋白产生的酸性乳清,或甚至经酸和凝乳酶凝结产生的混合乳清。这种原料可以是已通过离子交换和/或电渗析进行脱矿质化的乳清,被称作脱矿质化的乳清蛋白(DWP)。
此类基于乳清的蛋白质材料的来源可以是完全或部分去除了酪蛋白糖巨肽(CGMP)的甜乳清。这种被称作改性甜乳清(MSW)。将CGMP从甜乳清中去除使得蛋白质材料中的苏氨酸和色氨酸含量更接近其在人乳中的含量。用于从甜乳清中去除CGMP的方法在EP880902中有所描述。原料可以是DWP和MSW的混合物。其可以是浓缩物(WPC),其中乳清蛋白为35%至80%蛋白质,或者,如果乳清蛋白浓度大于95%蛋白质,则其可以是分离物(WPI)。WPC的一个示例为购自丹麦爱氏晨曦公司(Aria Foods,Denmark)的WPC 87 Lacprodan(R),WPI的一个示例为购自戴维斯柯食品国际公司(Davisco Foods International)(美国明尼苏达州(Minnesota USA))的Bipro(R)。
优选地,乳基蛋白质材料为乳清蛋白分离物(WPI)。
乳基蛋白质材料可在溶液或悬浮液中,并且可例如以按蛋白质材料重量计2%至30%、更优选地5%至20%、更优选地6%至10%的浓度存在。在一个实施方案中,乳基蛋白质材料以约6%的浓度存在。
向用于水解的原料中添加乳糖的优点在于:包含在该乳糖中的任何残留蛋白质均被水解。乳糖可以0.05至30%w/w、优选地0.10至20%w/w的浓度存在,或者在优选较低乳糖含量的情况下,以0.10%至1%、优选地0.10至0.20%(w/w)的浓度存在。在后一种情况下,最终产物可专用于具有低乳糖耐受性的个体。乳糖可例如通过超滤(产生UF乳清),任选地随后进行透析来除去。在一个实施方案中,乳糖以约2%的浓度存在。
原料可以是真水溶液或胶态水溶液的形式,或者粉末形式。在后一种情况下,粉末优选地溶于去离子水中以形成水溶液。
用于水解的酶
微生物碱性丝氨酸蛋白酶
微生物碱性丝氨酸蛋白酶优选地源自芽孢杆菌属物种,更优选地源自地衣芽孢杆菌。
在一个优选的实施方案中,碱性丝氨酸蛋白酶为枯草杆菌蛋白酶。
枯草杆菌蛋白酶的示例为源自芽孢杆菌的那些,例如枯草杆菌蛋白酶Novo、枯草杆菌蛋白酶Carlsberg、枯草杆菌蛋白酶BPN'、枯草杆菌蛋白酶309、枯草杆菌蛋白酶147和枯草杆菌蛋白酶168(在WO 89/06279中描述)以及蛋白酶PD138(WO 93/18140)。示例在WO98/0201 15、WO 01/44452、WO 01/58275、WO 01/58276、WO 03/006602和WO 04/099401中有所描述。
碱性丝氨酸蛋白酶的一个示例为枯草杆菌蛋白酶Carlsberg酶Uniprot P00780或其变体。
在一个特别优选的实施方案中,用于本发明的碱性丝氨酸蛋白酶为AlcalaseTM。
菠萝蛋白酶
术语‘菠萝蛋白酶’是本领域众所周知的。菠萝蛋白酶可指源自凤梨科成员的提取物,其包括各种硫醇蛋白酶,并且已知在体外和体内具有蛋白水解活性。
优选地,该提取物源自菠萝(Ananas comosus)的茎。该提取物可包含诸如半胱氨酸蛋白酶、淀粉酶、酸性磷酸酶、过氧化物酶和纤维素酶之类的组分。
该酶可具有以下EC编号:EC 3.4.22.32。
菠萝蛋白酶可包括:“茎菠萝蛋白酶”(UniProt P14518)或其变体。
曲霉蛋白酶
亮氨酸氨肽酶
优选地,本发明使用曲霉亮氨酸氨肽酶。更优选地,本发明使用米曲霉亮氨酸氨肽酶。
该酶可具有以下EC编号:EC 3.4.11.1。
亮氨酸氨肽酶优选地催化肽的N-末端残基水解,优选地催化亮氨酸残基水解。
由米曲霉表达的亮氨酸氨肽酶酶的示例包括LAPA(UniProt Q2U1F3)、LAP1(UniProt Q2PIT3)和LAP2(UniProt Q2ULM2)。
曲霉胃蛋白酶1
优选地,本发明使用源自曲霉属物种的曲霉胃蛋白酶1。更优选地,本发明使用米曲霉曲霉胃蛋白酶1。本领域常用的曲霉胃蛋白酶1的其他名称包括(尤其是)曲霉胃蛋白酶A、曲霉胃蛋白酶F和曲霉菌肽酶A(Aspergillopeptidase A)。
该酶可具有以下EC编号:EC 3.4.23.18。
曲霉胃蛋白酶1酶优选地催化具有宽谱特异性的多肽水解,优选地催化疏水残基之间的肽键水解。
芽孢杆菌蛋白酶
本发明的方法优选地使用来自芽孢杆菌属物种的蛋白酶。本发明的方法优选地使用枯草芽孢杆菌中性蛋白酶。本领域常用的枯草芽孢杆菌中性蛋白酶的其他名称包括(尤其是)芽孢杆菌溶素(bacillolysin)、芽孢杆菌金属内肽酶、巨大芽孢杆菌肽酶(megateriopeptidase)、芽孢杆菌中性蛋白酶和芽孢杆菌细胞外中性金属蛋白酶。
优选地,枯草芽孢杆菌中性蛋白酶来自枯草芽孢杆菌。
芽孢杆菌蛋白酶可具有以下EC编号:3.4.24.28。
芽孢杆菌蛋白酶的一个示例为NPRE(UniProt P68763)或其变体。
水解方法
用于进行水解方法的典型条件在现有技术中已有描述。温度可在约40℃至60℃的范围内(例如约55℃)。反应时间可为例如1至10小时,并且在开始水解之前的pH值可例如在6.5至8.5、优选地7.0至8.0的范围内。
pH可用已知的试剂(例如Ca(OH)2)来调节。
在一个实施方案中,该方法包括:
(i)第一水解步骤,包括用微生物碱性丝氨酸蛋白酶水解乳基蛋白质材料;以及
(ii)第二水解步骤,包括用菠萝蛋白酶联合来自曲霉的蛋白酶和来自芽孢杆菌的蛋白酶水解乳蛋白。
步骤(i)可进行例如约四小时,步骤(ii)可进行例如约六小时。
不管如何进行水解,都要对水解产物进行热处理,使进行水解的酶失活。这种热处理优选地包括预热水解物至75℃或以上(例如75℃至90℃)并将其在该温度下保持约0.1至30分钟以促进酶的自身消化。该处理之后可进行灭菌,优选地通过注射蒸汽或在热交换器中于超高温(例如在125℃至135℃)下灭菌30秒至3分钟。
可对由此得到的水解物进行澄清、微滤和/或超滤,以除去残留的蛋白质大片段。也可例如通过反渗透进行浓缩。然后可例如针对不同的应用通过冻干法、喷雾干燥或冷冻干燥进行干燥,或者甚至可进行后续处理。在后一种情况下,酶可在后续处理过程中失活。
本发明的水解物可具有以NPN/TN%含量表征的水解程度。NPN/TN%比例意指非蛋白氮除以总氮×100。非蛋白氮是蛋白质经酸沉淀后得到的氮级分。NPN/TN%可如Adler-Nissen J-,1979,J.Agric.Food Chem.,27(6),1256-1262(Adler-Nissen J-,1979年,《农业与食品化学杂志》,第27卷,第6期,第1256-1262页)中所详述的那样进行测定。
或者,水解程度可通过水解时释放的氨基氮的量来表征;游离氨基氮可与试剂诸如三硝基苯磺酸(TNBS)反应。
一般来讲,深度水解物的特征在于具有大于95%的NPN/TN%,而部分水解的水解物的特征在于具有在75%至85%范围内的NPN/TN%。在一个优选的实施方案中,本发明的水解物为具有在大于95%、96%、97%、98%或99%的范围内的NPN/TN%的深度水解物。
这些水解物的特征还可在于其至少95%的蛋白质/肽群具有<1000道尔顿的分子量。
所得的蛋白质水解物中肽的分子量分布可例如通过体积排阻色谱法(SEC)测定。在一个优选的实施方案中,本发明的水解物具有类似于或基本等同于的肽重量分布的肽重量分布。优选地,本发明的水解物具有类似于或基本等同于用猪胰酶代替本文提及的菠萝蛋白酶和曲霉蛋白酶及芽孢杆菌蛋白酶(尤其是代替菠萝蛋白酶、来自米曲霉的亮氨酸氨肽酶、来自米曲霉的曲霉胃蛋白酶1以及枯草芽孢杆菌中性蛋白酶)制得的水解物的肽重量分布的肽重量分布。换句话说,在本发明的上下文中,菠萝蛋白酶和曲霉蛋白酶及芽孢杆菌蛋白酶的共混物表现出与猪胰酶基本相同的水解活性。
在一个优选的实施方案中,本发明的水解物为深度水解物,并且由具有300Da至370Da、优选地320Da至360Da的中值分子量的肽组成。
可使用标准免疫测定法诸如ELISA检测评估水解物残留的抗原性。优选地,本发明的水解物呈现<0.1mg BLG当量/g蛋白质当量的残留β-乳球蛋白(BLG),并且最优选地为<0.01mg BLG当量/g蛋白质。
可将本发明的水解物,连同蛋白质水解物可为人类提供的任何其他益处,一起掺入到婴儿配方食品、较大婴儿配方食品、婴孩食物、婴儿谷物、成长乳、婴幼儿或儿童食品补充剂或者成人营养组合物,即所有治疗变态反应的制剂中。优选地,水解物用于1段婴儿配方食品。
由此类牛乳蛋白质水解物构成的旨在预防变态反应的当前低变应原性配方食品还包含其他营养物质,诸如动物油、植物油、淀粉、麦芽糖糊精、乳糖和蔗糖。
在本发明的一个实施方案中,本发明的水解物与所选益生菌联合使用,例如用于婴儿配方食品。所选益生菌可以是常规用于婴儿配方食品的益生菌中的任一种。优选地,益生菌是能够对变态反应提供额外或协同效应的益生菌。
可用于本发明的合适益生微生物的示例包括:酵母,诸如酵母属(Saccharomyces)、德巴利酵母属(Debaromyces)、假丝酵母属(Candida)、毕赤酵母属(Pichia)和球拟酵母属(Torulopsis);霉菌,例如曲霉属(曲霉)、根霉属(Rhizopus)、毛霉属(Mucor)和青霉菌属(Penicillium)以及球拟酵母属(Torulopsis);以及细菌,例如双歧杆菌属、拟杆菌属(Bacteroides)、梭菌属(Clostridium)、梭杆菌属(Fusobacterium)、蜜蜂球菌属(Melissococcus)、丙酸菌属(Propionibacterium)、链球菌属(Streptococcus)、肠球菌属(Enterococcus)、乳球菌属(Lactococcus)、葡萄球菌属(Staphylococcus)、消化链球菌属(Peptostrepococcus)、芽孢杆菌属(Bacillus)、片球菌属(Pediococcus)、微球菌属(Micrococcus)、明串珠菌属(Leuconostoc)、魏斯氏菌属(Weissella)、气球菌属(Aerococcus)、酒球菌属(Oenococcus)和乳杆菌属(Lactobacillus)。合适的益生微生物的具体示例为:酿酒酵母(Saccharomyces cereviseae)、凝结芽孢杆菌(Bacilluscoagulans)、地衣芽孢杆菌(Bacillus licheniformis)、枯草芽孢杆菌(Bacillussubtilis)、两歧双歧杆菌(Bifidobacterium bifidum)、婴儿双歧杆菌(Bifidobacteriuminfantis)、长双歧杆菌(Bifidobacterium longum)、屎肠球菌(Enterococcus faecium)、粪肠球菌(Enterococcus faecalis)、嗜酸乳杆菌(Lactobacillus acidophilus)、消化乳杆菌(Lactobacillus alimentarius)、干酪乳杆菌干酪亚种(Lactobacillus caseisubsp.casei)、干酪乳酸杆菌代田株(Lactobacillus casei Shirota)、弯曲乳杆菌(Lactobacillus curvatus)、德氏乳杆菌乳酸亚种(Lactobacillus delbruckiisubsp.lactis)、香肠乳杆菌(Lactobacillus farciminus)、加氏乳杆菌(Lactobacillusgasseri)、瑞士乳杆菌(Lactobacillus helveticus)、约氏乳杆菌(Lactobacillusjohnsonii)、罗伊氏乳杆菌Lactobacillus reuteri、鼠李糖乳杆菌(Lactobacillusrhamnosus(Lactobacillus GG))、清酒乳杆菌(Lactobacillus sake)、乳酸乳球菌(Lactococcus lactis)、变异微球菌(Micrococcus varians)、乳酸片球菌(Pediococcusacidilactici)、戊糖片球菌(Pediococcus pentosaceus)、乳酸片球菌(Pediococcusacidilactici)、嗜盐片球菌(Pediococcus halophilus)、粪链球菌(Streptococcusfaecalis)、嗜热链球菌(Streptococcus thermophilus)、肉葡萄球菌(Staphylococcuscarnosus)和木糖葡萄球菌(Staphylococcus xylosus)。
优选的益生细菌菌株包括:可以商标LGG购自芬兰维利奥公司(Valio Oy)的鼠李糖乳杆菌ATCC 53103,鼠李糖乳杆菌CGMCC 1.3724,副干酪乳杆菌(Lactobacillusparacasei)CNCM 1-2116,尤其由丹麦汉森集团公司(Christian Hansen company)以商标Bb 12销售的乳双歧杆菌(Bifidobacterium lactis)CNCM 1-3446,以及由日本森永乳业株式会社(Morigana Milk Industry Co.Ltd.)以商标BB536销售的长双歧杆菌ATCC BAA-999。
益生菌在每g组合物或每mL组合物中的量可例如为103至1012cfu,更优选地为106至1011cfu,甚至更优选地为104至109cfu,最优选地为107至109cfu。
本领域的技术人员将理解,在不脱离本文所公开的本发明范围的前提下,他们可以自由地组合本文所述的本发明的所有特征。
现将通过非限制性实施例来描述本发明的各优选特征和实施方案。
除非另外指明,本发明的实践将采用常规化学、分子生物学、微生物学、重组DNA和免疫学技术,这些技术均在本领域普通技术人员的能力范围之类。此类技术在文献中有所阐述。参见例如J.Sambrook,E.F.Fritsch,and T.Maniatis,1989,Molecular Cloning:ALaboratory Manual,Second Edition,Books 1-3,Cold Spring Harbor LaboratoryPress(J.Sambrook、E.F.Fritsch和T.Maniatis,1989年,《分子克隆:实验室手册》,第二版,第1-3册,冷泉港实验室出版社);Ausubel,F.M.et al.(1995 and periodic supplements;Current Protocols in Molecular Biology,ch.9,13,and 16,John Wiley&Sons,NewYork,N.Y.)(Ausubel,F.M.等人,1995年和定期增补;《分子生物学实验指南》,第9、13和16章,纽约州纽约约翰·威利父子公司);B.Roe,J.Crabtree,and A.Kahn,1996,DNAIsolation and Sequencing:Essential Techniques,John Wiley&Sons(B.Roe,J.Crabtree和A.Kahn,1996年,《DNA分离和测序:基本技术》,约翰·威利父子公司);J.M.Polak and James O’D.McGee,1990,In Situ Hybridization:Principles andPractice;Oxford University Press(J.M.Polak和James O’D.McGee,1990年,《原位杂交:原理和实践》,牛津大学出版社);M.J.Gait(Editor),1984,Oligonucleotide Synthesis:APractical Approach,Irl Press(M.J.Gait编,1984年,《寡核苷酸合成:实用方法》,Irl出版社);D.M.J.Lilley and J.E.Dahlberg,1992,Methods of Enzymology:DNA StructurePart A:Synthesis and Physical Analysis of DNA Methods in Enzymology,AcademicPress(D.M.J.Lilley和J.E.Dahlberg,1992年,《酶学方法:DNA结构A部分:DNA合成及物理分析》,《酶学方法》,学术出版社);以及E.M.Shevach and W.Strober,1992 and periodicsupplements,Current Protocols in Immunology,John Wiley&Sons,New York,NY(E.M.Shevach和W.Strober,1992年和定期增补,《免疫学实验指南》,纽约州纽约约翰·威利父子公司)。这些一般性文本中的每一个以引用的方式并入本文。
实施例
Alfaré和Althéra在制造过程中利用的是猪胰酶制剂。
植物和微生物蛋白酶的预混物意外地被确定为EHP生产中替代胰酶的合适替代物,并同时保持了水解产物特别是深度水解产物(EHP)的生物和生理特性。具体地讲,菠萝蛋白酶、微生物碱性丝氨酸蛋白酶、来自曲霉的蛋白酶和来自芽孢杆菌的蛋白酶的组合的使用已被确定为胰酶的合适替代物。
本发明人已建立用于制备乳蛋白质水解物的方法,该方法包括用上述试剂水解乳基蛋白质材料。
实施例1—方法
酶失活通过加热处理(90℃下加热5分钟)来实现,并且通过微滤和超滤去除所有残留的完整蛋白质和大肽。
实施例2—水解程度
NPN/TN%
水解程度使用非蛋白氮和总氮之间的比例(NPN/TN%)来测定。非蛋白氮级分通过蛋白质的酸沉淀获得。蛋白质水解后,产生的肽将归入“非蛋白氮”部分。因此,NPN/TN含量随水解程度的增大而增加。目标为在水解物中NPN/TN>=95%,过滤后NPN/TN>=99%。
SDS-PAGE
水解程度也采用快速凝胶电泳系统和银染通过SDS-PAGE电泳测定,以鉴定水解物中和过滤后任何残留的完整蛋白质和大肽(高于10kDa)。在样品变性(用SDS和加热处理)、还原(用DTT处理以还原二硫键)和酰化(加入碘乙酰胺以封阻硫醇基团)后,用聚丙烯酰胺凝胶分离样品中存在的总蛋白质和肽。尽管水解后仍存在一些完整的蛋白质和大肽,但过滤之后,通过将含2μg氮/μL溶液的样品溶液加样于凝胶上没有检测到与残留蛋白质和大肽相关的条带。
BLG-ELISA
使用可商购自拜发公司(r-Biopharm)的对β-乳球蛋白特异的酶联免疫吸附试验(ELISA)试剂盒,通过测定β-乳球蛋白的抗原性来评估残留抗原性的缺失情况。目标为在基于乳清的水解物中低于该试剂盒的检测限,即0.01mgβ-乳球蛋白当量/g蛋白质。
肽谱
对于通过水解产生并存在于过滤后的最终产物中的肽,使用体积排阻色谱法(SE-HPLC)基于其分子量进行表征。在样品溶解于0.1%TFA水溶液后,使用Superdex Peptide10/300GL体积排阻色谱柱(Superdex Peptide 10/300 GL Size-Exclusion column)以0.1%v/v TFA、30%v/v ACN水溶液作为流动相,得到可溶性肽的分子量分布(和中值)。肽的分子量分布在以下范围内测定:肽>2400Da、1200至2400Da、600至1200Da、240至600Da和<240Da。中值是这样的分子量:50%的肽具有高于该值的分子量。
游离AA/总AA%
水解时释放的游离氨基酸使用游离氨基酸和总氨基酸之间的比例(游离AA/总AA%)来测定。游离氨基酸含量通过采用离子交换色谱法(IEC)分离水性样品提取物中存在的游离氨基并用茚三酮试剂柱后衍生之后进行光度检测来获得。总氨基酸含量通过在氮气下在6mol/L盐酸(HCl)中水解测试部分(在水解前将胱氨酸过氧化成半胱氨酸并且将蛋氨酸过氧化成蛋氨酸砜以对酸稳定的氨基酸进行定量)并通过如上所述的离子交换色谱法分离单独的氨基酸来获得。
使用本发明的酶共混物的三个实验的结果示于表1中。
表1
所有结果都在目标值内。
Claims (24)
1.用于制备乳蛋白质水解物的方法,包括用微生物碱性丝氨酸蛋白酶联合菠萝蛋白酶、来自曲霉(Aspergillus)的蛋白酶和来自芽孢杆菌(Bacillus)的蛋白酶水解乳基蛋白质材料。
2.根据权利要求1所述的用于制备乳蛋白质水解物的方法,包括用微生物碱性丝氨酸蛋白酶联合菠萝蛋白酶、来自曲霉的两种蛋白酶和来自芽孢杆菌的蛋白酶水解乳基蛋白质材料。
3.根据权利要求2所述的用于制备乳蛋白质水解物的方法,其中所述来自曲霉的两种蛋白酶为亮氨酸氨肽酶和曲霉胃蛋白酶1,并且/或者来自芽孢杆菌的所述蛋白酶为枯草芽孢杆菌(Bacillus subtilis)中性蛋白酶。
4.根据权利要求3所述的方法,其中所述方法包括:
(iii)第一水解步骤,包括用所述微生物碱性丝氨酸蛋白酶水解所述乳基蛋白质材料;以及
(iv)第二水解步骤,包括用所述菠萝蛋白酶、所述亮氨酸氨肽酶、所述曲霉胃蛋白酶1和所述枯草芽孢杆菌中性蛋白酶水解所述乳蛋白。
5.根据前述权利要求中任一项所述的用于制备乳蛋白质水解物的方法,其中所述曲霉为米曲霉(Aspergillus oryzae),并且/或者所述芽孢杆菌为枯草芽孢杆菌。
6.根据权利要求1-4中任一项所述的方法,其中所述微生物碱性丝氨酸蛋白酶为枯草杆菌蛋白酶。
7.根据权利要求6所述的方法,其中所述枯草杆菌蛋白酶为枯草杆菌蛋白酶Carlsberg。
8.根据权利要求1-4中任一项所述的方法,其中所述碱性丝氨酸蛋白酶源自芽孢杆菌。
9.根据权利要求8所述的方法,其中所述芽孢杆菌是地衣芽孢杆菌(Bacilluslicheniformis)。
10.根据权利要求1-4中任一项所述的用于制备乳蛋白质水解物的方法,包括用来自地衣芽孢杆菌的微生物碱性丝氨酸蛋白酶联合菠萝蛋白酶、来自米曲霉的亮氨酸氨肽酶、来自米曲霉的曲霉胃蛋白酶1和枯草芽孢杆菌中性蛋白酶水解乳基蛋白质材料。
11.根据权利要求1-4中任一项所述的方法,其中所述碱性丝氨酸蛋白酶为AlcalaseTM。
12.根据权利要求1-4中任一项所述的方法,其中所述乳基蛋白质材料为乳清蛋白、酪蛋白或两者的混合物。
13.根据权利要求1-4中任一项所述的方法,其中所述乳基蛋白质材料为乳清蛋白。
14.根据权利要求1-4中任一项所述的方法,其中所述水解物进一步经受酶失活、微滤和/或超滤。
15.根据权利要求1-4中任一项所述的方法,其中所述蛋白质水解物为深度水解产物,其具有大于95%的NPN/TN%。
16.根据权利要求15所述的方法,其中所述蛋白质水解物具有大于99%的NPN/TN%。
17.包含通过根据前述权利要求中任一项所述的方法获得的乳基蛋白质水解物的组合物。
18.根据权利要求17所述的组合物,其中所述组合物为婴儿配方食品、儿童食品补充剂或成人营养组合物。
19.根据权利要求17所述的组合物,其中所述组合物为较大婴儿配方食品。
20.根据权利要求17所述的组合物,其中所述组合物为婴孩食物配方食品。
21.根据权利要求17-20中任何一项所述的组合物,其中所述组合物为低变应原性组合物。
22.微生物碱性丝氨酸蛋白酶联合菠萝蛋白酶、来自曲霉(Aspergillus)的蛋白酶和来自芽孢杆菌(Bacillus)的蛋白酶在制备包含乳基蛋白质材料水解物的组合物中的用途。
23.根据权利要求1至16中任一项所述的方法获得的乳蛋白质水解物在制备婴儿配方食品中的用途。
24.根据权利要求17至20中任何一项所述的组合物在制备用于减少或预防牛乳蛋白质变态反应(CMA)的产品中的用途。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15161655.4 | 2015-03-30 | ||
EP15161655 | 2015-03-30 | ||
PCT/EP2016/056080 WO2016156077A1 (en) | 2015-03-30 | 2016-03-21 | Milk-based protein hydrolysates and compositions made thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN107404922A CN107404922A (zh) | 2017-11-28 |
CN107404922B true CN107404922B (zh) | 2021-09-14 |
Family
ID=52784978
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201680017233.XA Active CN107404922B (zh) | 2015-03-30 | 2016-03-21 | 乳基蛋白质水解物及由其制备的组合物 |
Country Status (9)
Country | Link |
---|---|
US (1) | US10798963B2 (zh) |
EP (2) | EP3277103B1 (zh) |
JP (1) | JP6748099B2 (zh) |
CN (1) | CN107404922B (zh) |
AU (2) | AU2016239617B9 (zh) |
BR (1) | BR112017018491B1 (zh) |
CA (1) | CA2975814C (zh) |
ES (1) | ES2841939T3 (zh) |
WO (1) | WO2016156077A1 (zh) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112019006844A2 (pt) | 2016-10-05 | 2019-06-25 | Asit Biotech S A | prevenção de alergia |
FI3975733T3 (fi) * | 2019-05-29 | 2023-11-02 | Arla Foods Amba | Maittavia, pitkälle hydrolysoituja heraproteiinihydrolysaatteja |
CN114554872B (zh) | 2019-10-17 | 2024-04-16 | 雀巢产品有限公司 | 深度水解的婴儿配方食品 |
AU2020367247A1 (en) | 2019-10-17 | 2022-03-24 | Société des Produits Nestlé S.A. | Infant formula |
US20230026618A1 (en) | 2019-12-30 | 2023-01-26 | Societe Des Produits Nestle S.A. | Infant formula |
US10947552B1 (en) | 2020-09-30 | 2021-03-16 | Alpine Roads, Inc. | Recombinant fusion proteins for producing milk proteins in plants |
US10894812B1 (en) | 2020-09-30 | 2021-01-19 | Alpine Roads, Inc. | Recombinant milk proteins |
EP4222167A1 (en) | 2020-09-30 | 2023-08-09 | Nobell Foods, Inc. | Recombinant milk proteins and food compositions comprising the same |
EP4228436A1 (en) | 2020-10-16 | 2023-08-23 | Société des Produits Nestlé S.A. | Nutritional composition comprising human milk oligosaccharides |
EP4228435A1 (en) | 2020-10-16 | 2023-08-23 | Société des Produits Nestlé S.A. | Infant or young child formula |
JP2023547175A (ja) | 2020-11-10 | 2023-11-09 | ソシエテ・デ・プロデュイ・ネスレ・エス・アー | 栄養組成物 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015039135A1 (en) * | 2013-09-16 | 2015-03-19 | Glanbia Nutritionals (Ireland) PLC | Method for inhibiting aggregate formation during protein hydrolysis |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1547911A (en) * | 1976-01-19 | 1979-06-27 | Novo Industri As | Polypeptides |
DK589785A (da) * | 1985-12-18 | 1987-06-19 | Samuelsson Ernst Gunnar | Peptidpraeparat, fremgangsmaade til fremstilling deraf samt anvendelse af peptidpraeparatet |
EP0321603A1 (fr) | 1987-12-23 | 1989-06-28 | Societe Des Produits Nestle S.A. | Procédé de préparation d'un hydrolysat de protéines de lactosérum et d'un aliment hypoallergéniques |
DK6488D0 (da) | 1988-01-07 | 1988-01-07 | Novo Industri As | Enzymer |
FR2634104B1 (fr) | 1988-07-18 | 1991-10-18 | Union Coop Agricole | Hydrolysat partiel de proteines de lactoserum, procede enzymatique de preparation de cet hydrolysat, et aliment lacte dietetique hypoallergenique le contenant |
WO1993004593A1 (en) | 1991-08-30 | 1993-03-18 | Teagasc, The Agriculture And Food Development Authority | Hypoallergenic whey protein hydrolysate |
DK28792D0 (da) | 1992-03-04 | 1992-03-04 | Novo Nordisk As | Nyt enzym |
DK46793D0 (da) | 1993-04-26 | 1993-04-26 | Novo Nordisk As | Enzym |
DE69523791T2 (de) * | 1994-10-14 | 2002-09-05 | Morinaga Milk Industry Co Ltd | Peptid-mischung und produkte davon |
ATE257329T1 (de) | 1994-10-26 | 2004-01-15 | Novozymes As | Verfahren für die herstellung eines milch-protein-hydrolysates |
KR100561826B1 (ko) | 1996-11-04 | 2006-03-16 | 노보자임스 에이/에스 | 섭틸라제 변종과 조성물 |
EP0880902A1 (fr) | 1997-05-27 | 1998-12-02 | Nestlé Produkte AG | Procédé de traitement d'une matiére première lactosérique |
CA2394971C (en) | 1999-12-15 | 2016-01-19 | Novozymes A/S | Subtilase variants having an improved wash performance on egg stains |
ATE311762T1 (de) | 2000-02-08 | 2005-12-15 | Dsm Ip Assets Bv | Verwendung von säurestabilen subtilisinproteasen in tierfutter |
JP3640645B2 (ja) * | 2001-03-29 | 2005-04-20 | 森永乳業株式会社 | 焼成食品用起泡剤、それを用いた焼成食品、焼成食品の製造方法及び焼成食品用プレミックス |
AR033476A1 (es) | 2001-04-27 | 2003-12-17 | Florin Elena | Leche tratada resistente a la coagulacion acida para incrementar la biodisponibilidad de calcio, metodo para obtenerla, productos en base a leche elaborados con dicha leche tratada y metodos de elaboracion |
DK200101090A (da) | 2001-07-12 | 2001-08-16 | Novozymes As | Subtilase variants |
TWI317636B (en) | 2002-11-22 | 2009-12-01 | Meiji Dairies Corp | Nutritional compositions for liver disease patients or for patients underhigh levels of invasive stress |
DK1599215T3 (da) * | 2003-02-07 | 2010-11-15 | Campina Bv | Anvendelse af tryptophanrige peptider fra mælkeproteinhydrolysat til behandling af overvægt og fedme |
CA2526341C (en) | 2003-05-07 | 2013-02-19 | Novozymes A/S | Variant subtilisin enzymes (subtilases) |
JP5087407B2 (ja) | 2004-12-30 | 2012-12-05 | ジェネンコー・インターナショナル・インク | 酸性真菌プロテアーゼ |
EP2003989A1 (en) * | 2006-03-31 | 2008-12-24 | DSMIP Assets B.V. | Process for the hydrolysis of milk proteins |
EP2604125A1 (en) | 2008-12-31 | 2013-06-19 | Solae, Llc | Protein hydrolysate compositions having enhanced CCK releasing ability |
EP2436389A1 (en) | 2010-10-01 | 2012-04-04 | Nestec S.A. | Milk-based protein hydrolysates and infant formulae and nutritional compositions made thereof |
WO2014130007A1 (en) | 2013-02-19 | 2014-08-28 | Deerland Enzymes, Inc. | Proteolytic compositions for rapidly and extensively degrading protein supplements |
-
2016
- 2016-03-21 US US15/560,549 patent/US10798963B2/en active Active
- 2016-03-21 CN CN201680017233.XA patent/CN107404922B/zh active Active
- 2016-03-21 EP EP16714300.7A patent/EP3277103B1/en active Active
- 2016-03-21 CA CA2975814A patent/CA2975814C/en active Active
- 2016-03-21 JP JP2017548190A patent/JP6748099B2/ja active Active
- 2016-03-21 BR BR112017018491-5A patent/BR112017018491B1/pt active IP Right Grant
- 2016-03-21 AU AU2016239617A patent/AU2016239617B9/en active Active
- 2016-03-21 ES ES16714300T patent/ES2841939T3/es active Active
- 2016-03-21 EP EP20203804.8A patent/EP3804532A1/en active Pending
- 2016-03-21 WO PCT/EP2016/056080 patent/WO2016156077A1/en active Application Filing
-
2020
- 2020-11-09 AU AU2020267141A patent/AU2020267141B2/en active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015039135A1 (en) * | 2013-09-16 | 2015-03-19 | Glanbia Nutritionals (Ireland) PLC | Method for inhibiting aggregate formation during protein hydrolysis |
Also Published As
Publication number | Publication date |
---|---|
CA2975814A1 (en) | 2016-10-06 |
AU2020267141A1 (en) | 2020-12-03 |
JP2018509905A (ja) | 2018-04-12 |
EP3277103B1 (en) | 2020-11-11 |
AU2016239617B2 (en) | 2020-08-13 |
EP3804532A1 (en) | 2021-04-14 |
AU2020267141B2 (en) | 2022-07-28 |
US10798963B2 (en) | 2020-10-13 |
AU2016239617A1 (en) | 2017-08-17 |
US20180116270A1 (en) | 2018-05-03 |
EP3277103A1 (en) | 2018-02-07 |
CA2975814C (en) | 2023-06-27 |
CN107404922A (zh) | 2017-11-28 |
JP6748099B2 (ja) | 2020-08-26 |
BR112017018491A2 (pt) | 2018-04-24 |
BR112017018491B1 (pt) | 2022-11-16 |
ES2841939T3 (es) | 2021-07-12 |
AU2016239617B9 (en) | 2020-09-24 |
WO2016156077A1 (en) | 2016-10-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107404922B (zh) | 乳基蛋白质水解物及由其制备的组合物 | |
US20200330589A1 (en) | Milk-based protein hydrolysates and infant formulae and nutritional compositions made thereof | |
Mohanty et al. | Milk derived bioactive peptides and their impact on human health–A review | |
Abd El-Salam et al. | Preparation, properties, and uses of enzymatic milk protein hydrolysates | |
Tavares et al. | Optimisation, by response surface methodology, of degree of hydrolysis and antioxidant and ACE-inhibitory activities of whey protein hydrolysates obtained with cardoon extract | |
Korhonen et al. | Impact of processing on bioactive proteins and peptides | |
US6451552B1 (en) | Method for the selective degradation of milk protein in the presence of other milk proteins | |
Krunic et al. | The contribution of bioactive peptides of whey to quality of food products | |
Pérez-Escalante et al. | Antithrombotic activity of milk protein hydrolysates by lactic acid bacteria isolated from commercial fermented milks | |
Filiz et al. | Süt serum proteinleri ve türevlerinin biyolojik ve fizyolojik aktiviteleri | |
Tavano | Proteases as a tool in food biotechnology | |
Tüysüz et al. | Bioactive Peptides: Formation and Impact Mechanisms | |
BR122022011496B1 (pt) | Composições nutricionais produzidas a partir de hidrolisados de proteína à base de leite, e seus usos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20190715 Address after: Vevey Applicant after: SOCIETE DES PRODUITS NESTLE S. A. Address before: Vevey Applicant before: Nestle Products Technical Assistance Co., Ltd. |
|
TA01 | Transfer of patent application right | ||
GR01 | Patent grant | ||
GR01 | Patent grant |